$633.52
0.10% today
Nasdaq, Mar 26, 02:45 pm CET
ISIN
US75886F1075
Symbol
REGN
Sector
Industry

Regeneron Pharmaceuticals Stock price

$634.14
-89.33 12.35% 1M
-397.01 38.50% 6M
-78.19 10.98% YTD
-326.95 34.02% 1Y
-45.89 6.75% 3Y
+204.36 47.55% 5Y
+180.15 39.68% 10Y
Nasdaq, Closing price Tue, Mar 25 2025
-26.86 4.06%
ISIN
US75886F1075
Symbol
REGN
Sector
Industry

Key metrics

Market capitalization $69.33b
Enterprise Value $63.25b
P/E (TTM) P/E ratio 16.56
EV/FCF (TTM) EV/FCF 17.26
EV/Sales (TTM) EV/Sales 4.45
P/S ratio (TTM) P/S ratio 4.88
P/B ratio (TTM) P/B ratio 2.37
Revenue growth (TTM) Revenue growth 8.27%
Revenue (TTM) Revenue $14.20b
EBIT (operating result TTM) EBIT $4.11b
Free Cash Flow (TTM) Free Cash Flow $3.66b
Cash position $9.01b
EPS (TTM) EPS $38.29
P/E forward 17.45
P/S forward 4.77
EV/Sales forward 4.35
Short interest 2.48%
Show more

Create a Free Account to create an Regeneron Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Regeneron Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Regeneron Pharmaceuticals forecast:

19x Buy
68%
8x Hold
29%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a Regeneron Pharmaceuticals forecast:

Buy
68%
Hold
29%
Sell
4%

Financial data from Regeneron Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
14,202 14,202
8% 8%
100%
- Direct Costs 2,453 2,453
10% 10%
17%
11,749 11,749
8% 8%
83%
- Selling and Administrative Expenses 2,516 2,516
16% 16%
18%
- Research and Development Expense 4,635 4,635
16% 16%
33%
4,597 4,597
2% 2%
32%
- Depreciation and Amortization 483 483
15% 15%
3%
EBIT (Operating Income) EBIT 4,114 4,114
4% 4%
29%
Net Profit 4,413 4,413
12% 12%
31%

In millions USD.

Don't miss a Thing! We will send you all news about Regeneron Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Regeneron Pharmaceuticals Stock News

Negative
The Motley Fool
about 15 hours ago
As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded down a wide variety of stocks in both fields.
Neutral
GlobeNewsWire
about 18 hours ago
TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on Tuesday, April 29, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Neutral
GlobeNewsWire
one day ago
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Investors who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) prior to November 2023 and continue to hold any of those NASDAQ: REGN shares, should contact the Shareholders Foundation ...
More Regeneron Pharmaceuticals News

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Head office United States
CEO Leonard Schleifer
Employees 15,106
Founded 1988
Website www.regeneron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today